CardioPractice Cardio Talk

In this interview with Borja Ibáñez, National Centre for Cardiovascular Research CNIC and Fundacion Jimenez Diaz Hospital, Madrid - Spain, one of the Task Force co-ordinators of the ESC 2023 Guidelines for the management of acute coronary sydromes, and Riccardo Asteggiano, Laboratorio Analisi Ricerca Clinica, Turin - Italy, underline the complex aspects of long-term therapy after ACS, mainly concerning antithrombotic management and secondary prevention management.

With Bernard Iung, Hospital Bichat-Claude Bernard, Paris - France & Konstatinos Toutouzas, National & Kapodistrian University of Athens, Athens - Greece.

In this podcast, they discuss primary mitral regurgitation.

With Maurice Enriquez-Sarano, The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN & Marc Ferrini2, CH Saint Joseph and Saint Luc, Lyon, France.

In this podcast, Dr Maurice Enriquez-Sarano (The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA) joins Dr Marc Ferrini (Editor-in-Chief CardioPractice; CH Saint Joseph and Saint Luc, Lyon, France) to discuss our current understanding of mitral valve prolapse (MVP). The treatment of MVP has evolved in recent years, and we now know that a small fraction of myxomatous mitral valve prolapse patients may, over time, experience severe arrhythmia, irrespective of mitral regurgitation severity. Dr Sarano presents the current thinking on the diagnosis and the tools available for arrhythmic risk stratification.

With João Bicho Augusto, Hospital Professor Doutor Fernando Fonseca, Amadora - Portugal, Institute of Cardiovascular Science, University College London, London - United Kingdom & Victoria Johnson, University Hospital Frankfurt, Frankfurt am Main - Germany.

In this podcast, Dr João Bicho Augusto (Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal & Institute of Cardiovascular Science, University College London, London, United Kingdom) joins Dr Victoria Johnson (University Hospital Frankfurt, Frankfurt am Main, Germany) to discuss his CardioPractice article: Artificial intelligence in cardiovascular imaging algorithms - what is used in clinical routine?

With Panos E. Vardas, Department at Heraklion University, Hospital, Crete - Greece & Marc Ferrini, Editor-in-Chief CardioPractice; CH Saint Joseph and Saint Luc, Lyon - France.

In this podcast, Professor Panos E. Vardas (Department at Heraklion University, Hospital, Crete, Greece) joins Dr Marc Ferrini (CH Saint Joseph and Saint Luc, Lyon, France) to discuss how artificial intelligence can modify our daily cardiology practice.

With Nicolaus Marx, WTH University Hospital Aachen, Aachen - Germany & Ruxandra Christodorescu, University of Medicine and Pharmacy Victor Babes, Timisoara - Romania.   In this podcast, Professor Nicolaus Marx (WTH University Hospital Aachen, Aachen, Germany), Chair of Task Force of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes;  joins Associate Professor Ruxandra Christodorescu (University of Medicine and Pharmacy Victor Babes, Timisoara, Romania) to discuss lipids and diabetes.

With Dimitris RICHTER, Euroclinic of Athens, Athens - Greece & Heinz DREXEL, Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch - Austria.

In this podcast, Professor Heinz Drexel (Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria) joins Dr Dimitris Richter (Euroclinic of Athens, Athens, Greece) to discuss hypertriglyceridemia and residual cardiovascular risk.

1. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022 Nov 24;387(21):1923-1934.
2. Sosnowska B, Adach W, Surma S, Rosenson RS, Banach M. Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia. J Clin Med. 2022 Dec 25;12(1):168. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821629/
3. Gaba P, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Giugliano RP, Martens FMAC, Gibson CM, Ballantyne CM; REDUCE-IT Investigators. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. J Am Coll Cardiol. 2022 May 3;79(17):1660-1671. https://www.sciencedirect.com/science/article/pii/S0735109722005538?via%3Dihub
4. Drexel H, Tamargo J, Kaski JC, Lewis BS, Saely CH, Fraunberger P, Dobrev D, Komiyama M, Plattner T, Agewall S, Hasegawa K. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease? Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):570-582. https://academic.oup.com/ehjcvp/article/9/6/570/7199773?login=false
5. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563-74. https://www.nejm.org/doi/10.1056/NEJMoa1001282?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov